Stanley S Stylli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4074037/publications.pdf

Version: 2024-02-01

78 papers	3,069 citations	172207 29 h-index	168136 53 g-index
82 all docs	82 docs citations	82 times ranked	4649 citing authors

#	Article	IF	Citations
1	Photodynamic therapy of high grade glioma â€“ long term survival. Journal of Clinical Neuroscience, 2005, 12, 389-398.	0.8	199
2	Invadopodia: At the cutting edge of tumour invasion. Journal of Clinical Neuroscience, 2008, 15, 725-737.	0.8	190
3	Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation. Journal of Cell Science, 2009, 122, 2727-2740.	1.2	135
4	Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1785-1789.	3.3	134
5	Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies . OncoTargets and Therapy, 2019, Volume 12, 635-645.	1.0	124
6	Optical coherence tomography predicts visual outcome for pituitary tumors. Journal of Clinical Neuroscience, 2015, 22, 1098-1104.	0.8	121
7	The emergent role of exosomes in glioma. Journal of Clinical Neuroscience, 2017, 35, 13-23.	0.8	115
8	The role of Stat3 in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 907-911.	0.8	104
9	Phase I and Pharmacokinetic Study of Photodynamic Therapy for High-Grade Gliomas Using a Novel Boronated Porphyrin. Journal of Clinical Oncology, 2001, 19, 519-524.	0.8	93
10	Photodynamic therapy of cerebral glioma â€“ A review Part II â€“ Clinical studies. Journal of Clinical Neuroscience, 2006, 13, 709-717.	0.8	86
11	Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. Journal of Clinical Neuroscience, 2004, 11, 584-596.	0.8	81
12	Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. Journal of Clinical Neuroscience, 2014, 21, 735-740.	0.8	79
13	Selective Uptake of Hematoporphyrin Derivative into Human Cerebral Glioma. Neurosurgery, 1990, 26, 248-254.	0.6	78
14	Overexpression of Hyaluronan Synthase-2 Reduces the Tumorigenic Potential of Glioma Cells Lacking Hyaluronidase Activity. Neurosurgery, 2002, 50, 1311-1318.	0.6	72
15	Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 12126-12130.	3.3	67
16	The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy. Current Drug Targets, 2014, 15, 1341-1353.	1.0	65
17	Mouse models of glioma. Journal of Clinical Neuroscience, 2015, 22, 619-626.	0.8	64
18	The role of interleukinâ€‘6â€‘STAT3 signalling in glioblastoma (Review). Oncology Letters, 2018, 16, 4095-4104.	0.8	61

#	Article	IF	Citations
19	Photodynamic therapy of cerebral glioma â€“ A review Part I â€“ A biological basis. Journal of Clinical Neuroscience, 2006, 13, 615-625.	0.8	55
20	miRNA expression profiling of cerebrospinal fluid in patients with aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2017, 126, 1131-1139.	0.9	55
21	Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy. British Journal of Cancer, 1992, 65, 321-328.	2.9	50
22	STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Molecular and Cellular Endocrinology, 2017, 451, 15-23.	1.6	49
23	Repair mechanisms help glioblastoma resist treatment. Journal of Clinical Neuroscience, 2015, 22, 14-20.	0.8	48
24	Prognostic significance of Tks5 expression in gliomas. Journal of Clinical Neuroscience, 2012, 19, 436-442.	0.8	47
25	MicroRNA as potential biomarkers in Glioblastoma. Journal of Neuro-Oncology, 2015, 125, 237-248.	1.4	47
26	Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18 F]fluoromisonidazole (FMISO). Nuclear Medicine and Biology, 2002, 29, 191-197.	0.3	42
27	Novel Treatment Strategies for Glioblastoma. Cancers, 2020, 12, 2883.	1.7	42
28	A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker. PLoS ONE, 2018, 13, e0189452.	1.1	39
29	Glycogen synthase kinase-3Î² (GSK-3Î²) and its dysregulation in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 1185-1192.	0.8	36
30	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	1.2	31
31	Extracellular vesicles and their role in glioblastoma. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 227-252.	2.7	30
32	Two-photon absorption cross-sections and time-resolved fluorescence imaging using porphyrin photosensitisers. Photochemical and Photobiological Sciences, 2007, 6, 1019-1026.	1.6	27
33	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. Cancer Biology and Therapy, 2014, 15, 623-632.	1.5	27
34	Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System. Cells, 2019, 8, 1364.	1.8	27
35	Serum microRNA is a biomarker for post-operative monitoring in glioma. Journal of Neuro-Oncology, 2020, 149, 391-400.	1.4	27
36	The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. Oncotarget, 2015, 6, 21301-21314.	0.8	27

#	Article	IF	Citations
37	IL-10 in glioma. British Journal of Cancer, 2021, 125, 1466-1476.	2.9	26
38	Circulating tumor stem cells and glioblastoma: A review. Journal of Clinical Neuroscience, 2019, 61, 5-9.	0.8	24
39	The biocompatibility of BioGlue with the cerebral cortex: a pilot study. Journal of Clinical Neuroscience, 2004, 11, 631-635.	0.8	23
40	Synovial ablation in a rabbit rheumatoid arthritis model using photodynamic therapy. ANZ Journal of Surgery, 2002, 72, 517-522.	0.3	22
41	Expression of the adaptor protein Tks5 in human cancer: Prognostic potential. Oncology Reports, 2014, 32, 989-1002.	1.2	22
42	Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Medical Oncology, 2016, 33, 53.	1.2	21
43	Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures. Experimental and Molecular Pathology, 2018, 105, 23-31.	0.9	21
44	Prognostic Utility of Optical Coherence Tomography for Long-Term Visual Recovery Following Pituitary Tumor Surgery. American Journal of Ophthalmology, 2020, 218, 247-254.	1.7	21
45	Extracellular Vesicles Secreted by Glioma Stem Cells Are Involved in Radiation Resistance and Glioma Progression. International Journal of Molecular Sciences, 2022, 23, 2770.	1.8	21
46	Induction of CD44 expression in stab wounds of the brain: long term persistence of CD44 expression. Journal of Clinical Neuroscience, 2000, 7, 137-140.	0.8	19
47	Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. Journal of Neurosurgery, 2018, 129, 598-610.	0.9	18
48	Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma. Cancer Investigation, 2019, 37, 144-155.	0.6	17
49	Using bioluminescence imaging in glioma research. Journal of Clinical Neuroscience, 2015, 22, 779-784.	0.8	16
50	Aluminium phthalocyanine mediated photodynamic therapy in experimental malignant glioma. Journal of Clinical Neuroscience, 1995, 2, 146-151.	0.8	15
51	Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. Cancers, 2018, 10, 526.	1.7	15
52	Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs. Translational Oncology, 2018, 11, 1406-1418.	1.7	15
53	Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance. Advances in Experimental Medicine and Biology, 2019, 1139, 1-21.	0.8	14
54	Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma. British Journal of Cancer, 1996, 73, 514-521.	2.9	13

#	Article	IF	Citations
55	Dipyridophenazine Complexes of Cobalt(III): DNA Photocleavage and Photobiology. Australian Journal of Chemistry, 2005, 58, 206.	0.5	13
56	Tumour stem cells in schwannoma: A review. Journal of Clinical Neuroscience, 2019, 62, 21-26.	0.8	13
57	Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2019, 130, 1446-1452.	0.9	13
58	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	2.0	11
59	A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: Increasing glutamate uptake with PPARÎ³ agonists. Journal of Clinical Neuroscience, 2015, 22, 21-28.	0.8	10
60	Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer. Cellular Signalling, 2019, 57, 2-9.	1.7	10
61	Cancer exosomes in cerebrospinal fluid. Translational Cancer Research, 2017, 6, S1352-S1370.	0.4	10
62	Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs. Cancers, 2020, 12, 2888.	1.7	9
63	Temporal patterns of visual recovery following pituitary tumor resection: A prospective cohort study. Journal of Clinical Neuroscience, 2021, 86, 252-259.	0.8	9
64	Phthalocyanine photosensitizers for the treatment of brain tumours. Journal of Clinical Neuroscience, 1995, 2, 64-72.	0.8	8
65	Antitumour effect of MX2, a new morpholino anthracycline against C6 glioma cells and its cytotoxic effect in combination with photodynamic therapy. Journal of Clinical Neuroscience, 1994, 1, 47-52.	0.8	7
66	Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. Biochemical and Biophysical Research Communications, 2006, 351, 1018-1023.	1.0	7
67	Evaluation of a morpholinothiolporphyrin for use in photodynamic therapy. British Journal of Cancer, 1994, 70, 398-400.	2.9	6
68	Association between elevated cerebrospinal fluid D-dimer levels and delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. Journal of Clinical Neuroscience, 2020, 76, 177-182.	0.8	5
69	Novel Treatment Strategies for Glioblastomaâ€"A Summary. Cancers, 2021, 13, 5868.	1.7	5
70	The renin-angiotensin system in central nervous system tumors and degenerative diseases. Frontiers in Bioscience, 2021, 26, 628.	0.8	4
71	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro, 2022, 2, 74-92.	0.3	3
72	PHOTODYNAMIC THERAPY IN THE TREATMENT OF SUBCUTANEOUSLY IMPLANTED HUMAN BLADDER TUMOUR. ANZ Journal of Surgery, 1992, 62, 643-649.	0.3	2

#	Article	IF	Citations
73	Peripheral biomarkers in glioblastoma patientsâ€"is it all just HOTAIR?. Non-coding RNA Investigation, 0, 2, 32-32.	0.6	2
74	Identification and isolation of slow-cycling glioma stem cells. Methods in Cell Biology, 2022, , 21-30.	0.5	2
75	Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. Cancer Chemotherapy and Pharmacology, 1997, 40, 202-208.	1.1	1
76	Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. Cancer Chemotherapy and Pharmacology, 1998, 41, 423-426.	1.1	1
77	Two-photon characterization and microscopy of porphyrin photosensitisers. , 2007, , .		0
78	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention. , 2021, , 319-334.		0